Does the media favor PRLD or MRVI?

In the previous week, Prelude Therapeutics had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 2 mentions for Prelude Therapeutics and 1 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.34 beat Prelude Therapeutics' score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRLD or MAZE more profitable?

Maze Therapeutics' return on equity of -36.62% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% Maze Therapeutics N/A -36.62% -31.78%

Does the media prefer PRLD or MAZE?

In the previous week, Prelude Therapeutics and Prelude Therapeutics both had 2 articles in the media. Maze Therapeutics' average media sentiment score of 1.67 beat Prelude Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maze Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor PRLD or PAHC?

In the previous week, Phibro Animal Health had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Phibro Animal Health and 2 mentions for Prelude Therapeutics. Phibro Animal Health's average media sentiment score of 0.31 beat Prelude Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phibro Animal Health 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, PRLD or AVLN?

Avalyn Pharma has lower revenue, but higher earnings than Prelude Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prelude Therapeutics $12.14M 28.73 -$99.50M -$1.00 N/A Avalyn Pharma N/A N/A N/A N/A N/A

Is PRLD or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% Avalyn Pharma N/A N/A N/A

Does the media refer more to PRLD or AVLN?

In the previous week, Avalyn Pharma had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Avalyn Pharma and 2 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.00 equaled Avalyn Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PRLD or DMRA more profitable?

Prelude Therapeutics' return on equity of -118.24% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Prelude Therapeutics (PRLD) Competitors

$4.38 +0.06 (+1.39%)

As of 04:00 PM Eastern

Compare

PRLD vs. MRVI, MAZE, PAHC, AVLN, and DMRA

Should you buy Prelude Therapeutics stock or one of its competitors? MarketBeat compares Prelude Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prelude Therapeutics include Maravai LifeSciences (MRVI), Maze Therapeutics (MAZE), Phibro Animal Health (PAHC), Avalyn Pharma (AVLN), and Damora Therapeutics, Inc. Common Stock (DMRA). These companies are all part of the "pharmaceutical products" industry.

How does Prelude Therapeutics compare to Maravai LifeSciences?

Prelude Therapeutics (NASDAQ:PRLD) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Prelude Therapeutics has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	28.73	-$99.50M	-$1.00	N/A
Maravai LifeSciences	$185.74M	7.46	-$130.77M	-$0.71	N/A

Prelude Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Prelude Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Maravai LifeSciences has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

In the previous week, Prelude Therapeutics had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 2 mentions for Prelude Therapeutics and 1 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.34 beat Prelude Therapeutics' score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prelude Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 75.04%. Maravai LifeSciences has a consensus price target of $5.50, suggesting a potential upside of 2.42%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Prelude Therapeutics beats Maravai LifeSciences on 10 of the 15 factors compared between the two stocks.

How does Prelude Therapeutics compare to Maze Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Prelude Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Maze Therapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market.

79.7% of Prelude Therapeutics shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Maze Therapeutics' return on equity of -36.62% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Maze Therapeutics	N/A	-36.62%	-31.78%

Prelude Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 75.04%. Maze Therapeutics has a consensus target price of $66.00, indicating a potential upside of 149.91%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Prelude Therapeutics and Prelude Therapeutics both had 2 articles in the media. Maze Therapeutics' average media sentiment score of 1.67 beat Prelude Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maze Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Prelude Therapeutics has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	28.73	-$99.50M	-$1.00	N/A
Maze Therapeutics	$20M	73.08	-$131.12M	-$2.53	N/A

Summary

Maze Therapeutics beats Prelude Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Prelude Therapeutics compare to Phibro Animal Health?

Prelude Therapeutics (NASDAQ:PRLD) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Prelude Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Phibro Animal Health has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Phibro Animal Health has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	28.73	-$99.50M	-$1.00	N/A
Phibro Animal Health	$1.30B	0.96	$48.26M	$2.33	13.10

Prelude Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 75.04%. Phibro Animal Health has a consensus price target of $42.50, suggesting a potential upside of 39.21%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Prelude Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phibro Animal Health has a net margin of 6.35% compared to Prelude Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Phibro Animal Health	6.35%	37.14%	8.57%

In the previous week, Phibro Animal Health had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Phibro Animal Health and 2 mentions for Prelude Therapeutics. Phibro Animal Health's average media sentiment score of 0.31 beat Prelude Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phibro Animal Health	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Phibro Animal Health beats Prelude Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to Avalyn Pharma?

Prelude Therapeutics (NASDAQ:PRLD) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Prelude Therapeutics presently has a consensus target price of $7.67, suggesting a potential upside of 75.04%. Avalyn Pharma has a consensus target price of $59.00, suggesting a potential upside of 82.72%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Avalyn Pharma has lower revenue, but higher earnings than Prelude Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	28.73	-$99.50M	-$1.00	N/A
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A

79.7% of Prelude Therapeutics shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Avalyn Pharma had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Avalyn Pharma and 2 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.00 equaled Avalyn Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avalyn Pharma's return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Avalyn Pharma	N/A	N/A	N/A

Summary

Avalyn Pharma beats Prelude Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Prelude Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Prelude Therapeutics (NASDAQ:PRLD) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Prelude Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	28.73	-$99.50M	-$1.00	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

In the previous week, Prelude Therapeutics had 2 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 2 mentions for Prelude Therapeutics and 0 mentions for Damora Therapeutics, Inc. Common Stock. Prelude Therapeutics' average media sentiment score of 0.00 equaled Damora Therapeutics, Inc. Common Stock'saverage media sentiment score.

Company	Overall Sentiment
Prelude Therapeutics	Neutral
Damora Therapeutics, Inc. Common Stock	Neutral

Prelude Therapeutics currently has a consensus target price of $7.67, suggesting a potential upside of 75.04%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $42.43, suggesting a potential upside of 84.95%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Prelude Therapeutics' return on equity of -118.24% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Prelude Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Summary

Prelude Therapeutics beats Damora Therapeutics, Inc. Common Stock on 8 of the 14 factors compared between the two stocks.

Get Prelude Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRLD vs. The Competition

Export

Metric	Prelude Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$344.07M	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-4.38	18.43	24.92	23.98
Price / Sales	28.73	327.41	528.51	109.04
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	4.02	4.11	10.79	6.50
Net Income	-$99.50M	$64.45M	$3.56B	$336.88M
7 Day Performance	4.29%	2.24%	1.67%	-0.22%
1 Month Performance	2.58%	1.04%	0.43%	0.77%
1 Year Performance	421.43%	30.05%	32.84%	31.57%

Prelude Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRLD Prelude Therapeutics	3.639 of 5 stars	$4.38 +1.4%	$7.67 +75.0%	+402.0%	$344.07M	$12.14M	N/A	120	News Coverage
MRVI Maravai LifeSciences	2.5257 of 5 stars	$5.14 +3.5%	$5.50 +7.1%	+154.9%	$1.33B	$185.74M	N/A	610
MAZE Maze Therapeutics	3.1638 of 5 stars	$23.69 -2.4%	$66.00 +178.7%	+128.7%	$1.31B	$167.50M	N/A	121	Positive News
PAHC Phibro Animal Health	4.8636 of 5 stars	$31.59 -2.2%	$42.50 +34.6%	+30.1%	$1.28B	$1.30B	13.56	2,475	Upcoming Earnings
AVLN Avalyn Pharma	4.6721 of 5 stars	$28.15 -2.1%	$59.00 +109.6%	N/A	$1.25B	N/A	N/A	51	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRLD) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prelude Therapeutics (PRLD) Competitors

PRLD vs. MRVI, MAZE, PAHC, AVLN, and DMRA

How does Prelude Therapeutics compare to Maravai LifeSciences?

Summary

How does Prelude Therapeutics compare to Maze Therapeutics?

Summary

How does Prelude Therapeutics compare to Phibro Animal Health?

Summary

How does Prelude Therapeutics compare to Avalyn Pharma?

Summary

How does Prelude Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prelude Therapeutics (PRLD) Competitors

PRLD vs. MRVI, MAZE, PAHC, AVLN, and DMRA

How does Prelude Therapeutics compare to Maravai LifeSciences?

Which has stronger valuation & earnings, PRLD or MRVI?

Is PRLD or MRVI more profitable?

Which has more risk & volatility, PRLD or MRVI?

Does the media favor PRLD or MRVI?

Do analysts rate PRLD or MRVI?

Do institutionals and insiders hold more shares of PRLD or MRVI?

Summary

How does Prelude Therapeutics compare to Maze Therapeutics?

Which has more volatility & risk, PRLD or MAZE?

Do insiders and institutionals believe in PRLD or MAZE?

Is PRLD or MAZE more profitable?

Do analysts rate PRLD or MAZE?

Does the media prefer PRLD or MAZE?

Which has preferable earnings and valuation, PRLD or MAZE?

Summary

How does Prelude Therapeutics compare to Phibro Animal Health?

Do insiders & institutionals hold more shares of PRLD or PAHC?

Which has more volatility & risk, PRLD or PAHC?

Which has better valuation & earnings, PRLD or PAHC?

Do analysts prefer PRLD or PAHC?

Is PRLD or PAHC more profitable?

Does the media favor PRLD or PAHC?

Summary

How does Prelude Therapeutics compare to Avalyn Pharma?

Do analysts recommend PRLD or AVLN?

Which has preferable earnings & valuation, PRLD or AVLN?

Do institutionals & insiders hold more shares of PRLD or AVLN?

Does the media refer more to PRLD or AVLN?

Is PRLD or AVLN more profitable?

Summary

How does Prelude Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Which has preferable earnings and valuation, PRLD or DMRA?

Does the media prefer PRLD or DMRA?

Do analysts recommend PRLD or DMRA?

Do institutionals & insiders have more ownership in PRLD or DMRA?

Is PRLD or DMRA more profitable?

Which has more volatility & risk, PRLD or DMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools